A Phase 1, Open-Label, Parallel Group Trial to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single Intravenous Dose of TAK-954
Phase of Trial: Phase I
Latest Information Update: 31 Dec 2018
At a glance
- Drugs TD 8954 (Primary)
- Indications Gastrointestinal motility disorders
- Focus Pharmacokinetics
- Sponsors Takeda
- 19 Dec 2018 Status changed from active, no longer recruiting to completed.
- 05 Dec 2018 Planned End Date changed from 21 Nov 2018 to 10 Dec 2018.
- 05 Dec 2018 Status changed from recruiting to active, no longer recruiting.